Beta Bionics Inc
NASDAQ:BBNX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Beta Bionics Inc
NASDAQ:BBNX
|
US |
|
A
|
American Battery Technology Co
NASDAQ:ABAT
|
US |
|
O
|
Ottakringer Getraenke AG
VSE:OTS
|
AT |
|
S
|
SAB Zenzele Kabili Holdings (RF) Ltd
JSE:SZK
|
ZA |
|
Citizens Financial Group Inc
NYSE:CFG
|
US |
|
L3harris Technologies Inc
NYSE:LHX
|
US |
|
Wuxi Shangji Automation Co Ltd
SSE:603185
|
CN |
|
O
|
Openbase Inc
KOSDAQ:049480
|
KR |
|
MBB SE
F:MBB
|
DE |
|
Samsung Electronics Co Ltd
LSE:SMSD
|
KR |
|
Cheer Holding Inc
NASDAQ:CHR
|
CN |
Beta Bionics Inc
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 279 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 279 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
